In addition to AraC, the activity of camptothecin (CPT), a topoisomerase inhibitor was also found correlated to SLFN11 expression in 31 B-cell-derived cancer cell lines available in the GDSC database (Fig 5A right). This evidence concerns the gene SLFN11 and cancer.